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Background: Several aggregate data meta-analyses suggest that treatment guided by the serum concentration of
natriuretic peptides (B-type natriuretic peptide (BNP) or its derivative N-terminal pro-B-type natriuretic peptide
(NT-BNP)) reduces all-cause mortality compared with usual care in patients with heart failure (HF). We propose to
conduct a meta-analysis using individual participant data (IPD) to estimate the effect of BNP-guided therapy on
clinical outcomes, and estimate the extent of effect modification for clinically important subgroups.
Methods: We will use standard systematic review methods to identify relevant trials and assess study quality. We
will include all randomized controlled trials (RCTs) of BNP-guided treatment for HF that report a clinical outcome.
The primary outcome will be time to all-cause mortality. We will collate anonymized, individual patient data into a
single database, and carry out appropriate data checks. We will use fixed-effects and random-effects meta-analysis
methods to combine hazard ratios (HR) estimated within each RCT, across all RCTs. We will also include a meta-analysis
and meta-regression analyses based on aggregate data, and combine IPD with aggregate data if we obtain IPD for a
subset of trials.
Discussion: The IPD meta-analysis will allow us to estimate how patient characteristics modify treatment benefit, and
to identify relevant subgroups of patients who are likely to benefit most from BNP-guided therapy. This is important
because aggregate meta-analyses have suggested that clinically relevant subgroup effects exist, but these analyses
have been unable to quantify the effects reliably or precisely.
Trials registration: PROSPERO 2013: CRD42013005335
Keywords: Heart failure, B-type natriuretic peptide, individual participant data meta-analysisBackground
Heart failure (HF) is one of the most costly conditions
to manage, and markedly impairs the patient's quality of
life. It has an estimated prevalence of 6 to 10% in people
over 65 years of age [1], increasing to 14% in people over
85 years [2]. Prevalence is expected to increase in the fu-
ture because of the ageing population and improved sur-
vival of people with ischemic heart disease. The prognosis
of patients with HF is poor; up to 40% of newly diagnosed
patients die within 1 year [3,4].* Correspondence: maria.pufulete@bristol.ac.uk
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unless otherwise stated.Pharmacological treatment for HF is complex, and in-
cludes angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, beta-blockers, and min-
eralocorticoid receptor antagonists. Clinical guidelines
recommend up-titration of these drugs to target (or max-
imally tolerated) doses, but this is difficult to achieve in
practice, given the number of drugs involved and the fact
that the sequence of addition and up-titration is based
largely on clinician judgement. The use of biomarker test
results to guide up-titration of medication has been pro-
posed as a more objective means of achieving optimal
therapy in patients with HF.
Several randomized controlled trials (RCTs) have assessed
whether using serum natriuretic peptide levels (B-typel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Pufulete et al. Systematic Reviews 2014, 3:41 Page 2 of 8
http://www.systematicreviewsjournal.com/content/3/1/41natriuretic peptide (BNP) or its derivative N-terminal
pro-B-type natriuretic peptide (NT-BNP); collectively
referred to here as 'BNP') to guide up-titration of medica-
tion improves clinical outcomes. BNP reflects cardiac
function. BNP levels rise in line with the severity of symp-
toms [5] and are lowered by drugs used to treat HF, and
this sequence (monitoring and consequent changes in
medication) is associated with improved clinical outcome
[6-9]. BNP predicts adverse outcomes in HF and provides
powerful risk stratification with respect to mortality across
the entire range of HF stages [10].
To date there have been four aggregate data meta-
analyses of RCTs of BNP-guided therapy, which assessed
6 (n = 1627), 8 (n = 1726), 11 (n = 2414) and 12 (n =
2686) RCTs [6-9], respectively, with patients followed for
an average of 12 to 16 months. All reported a reduction
in all-cause mortality in the BNP-guided therapy group
compared with usual care (symptom-based therapy)
(hazard ratio (HR) = 0.69, 95% confidence interval (CI)
0.55 to 0.86 [6]; risk ratio (RR) = 0.76, 95% CI 0.63 to
0.91 [7]; RR = 0.83, 95% CI 0.69 to 0.99 [8]; odds ratio
(OR) = 0.74, 95% CI 0.60 to 0.91 [9]). The two latter
meta-analyses, which assessed 11 and 12 RCTs, respect-
ively, also reported a decrease in HF-related rehospitali-
zation (RR = 0.65, 95% CI 0.50 to 0.84 [8]; OR = 0.55,
95% CI 0.40 to 0.77 [9]). In subgroup analyses of three
meta-analyses [7-9] the reduction in mortality was ob-
served only in younger patients (≤75 years), although
none of these meta-analyses formally quantified treat-
ment effect modification. The identification of relevant
treatment subgroups is important because it is known
that some patients do not benefit from, and may even be
harmed by, intensive drug therapy for HF. For example,
in elderly patients with multiple comorbidities, the risks
of adverse outcomes from intensified therapy might out-
weigh any benefits, because up-titration of diuretics,
ACE inhibitors, and beta-blockers may worsen clinical
outcomes in such patients by causing hypotension and
aggravating renal failure [11].
The main limitation of aggregate data meta-analysis is
that variation in treatment effects across individuals with
different effect modifiers cannot be explored. If sub-
group analyses are presented, the definition of the sub-
groups may vary across trials, and results may be
reported inconsistently, or be incompatible in other ways
across trials (for example, outcomes reported at different
points in time or with different periods of follow-up).
Findings may also be selectively reported, so that sub-
group effects are presented only when they are statistically
significant. Individual participant data (IPD) meta-analysis
uses ‘raw’ individual-level data obtained from each study
to estimate an overall effect, avoiding the limitations aris-
ing from inconsistencies in conduct and reporting across
trials. In particular, a powerful and detailed analysis oftreatment effect modification can be undertaken, using
within-trial data to estimate how the characteristics of the
patients modify treatment benefit [12].
IPD meta-analysis is widely regarded as the gold stand-
ard, and has several other advantages over aggregate data
meta-analysis. It allows a more flexible analysis of out-
comes, including time-to-event and subgroup analyses,
detailed data checking to ensure consistency, and an as-
sessment of the quality of randomization and follow-up.
The IPD can also be updated with more recent follow-up
information. We propose to conduct an IPD meta-analysis
to determine whether BNP-guided therapy improves out-
comes in patients with HF. This will also allow us to de-
termine which subgroups of patients are likely to benefit
most from BNP-guided therapy, and possibly identify spe-
cific components of the interventions responsible for the
improved outcomes observed in individual RCTs. An
existing IPD meta-analysis of 8 RCTs (including 2,000 pa-
tients) was published recently [13]. We will produce an
up-to-date IPD meta-analysis using data from more recent
trials in accordance with this protocol. If we do not obtain
IPD for all the eligible trials, we will combine IPD with ag-
gregate data (for trials that have not provided IPD), so that
we can still exploit the benefits of IPD while synthesizing
evidence from all the available studies [14].
Aims and objectives
The main aim of the IPD meta-analysis is to determine
the clinical effectiveness of BNP-guided therapy versus
standard care. Specific objectives are as follows:
1. To estimate the effect of treatment guided by serial
BNP monitoring on clinical outcomes (time to all-cause
mortality, death related to HF, cardiovascular death,
all-cause hospital admission, hospital admission for
HF, adverse events, quality of life) compared with
usual care (symptom-based therapy).
2. To estimate the extent of effect modification for key
outcomes including all-cause mortality and hospital
admission for clinically important subgroups. The
following subgroups have been specified through
consensus with clinical members of the review team:
age, gender, type of HF, severity of HF, baseline BNP
levels, New York Heart Association (NYHA) class, left
ventricular ejection fraction (LVEF), blood pressure
(BP), body mass index (BMI), atrial fibrillation (AF),
diabetes, cardiomyopathy, and risk score for mortality.
3. To quantify the extent to which improved outcomes
are explained by up-titration of medication and/or
reduction in BNP levels. This may be possible only
for a subset of trials, or not at all, depending on the
availability of IPD describing titration of medication
in trial datasets.
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to describe the safety of BNP-guided therapy in patients
with HF.
Methods
The IPD meta-analysis will be conducted in accordance
with the methods recommended by the IPD Meta-analysis
Methods Group of the Cochrane Collaboration [15] and
other published guidelines [16].
Criteria for considering studies for the review
Types of studies
We will include RCTs of BNP-guided treatment for HF
that report an eligible outcome (see below).
Population
We will include all patients aged over 18 years who are
being treated for HF in primary or secondary care.
Interventions
Treatment guided by serial BNP or NT-BNP measure-
ments (BNP-guided therapy) or treatment guided by clin-
ical assessment (usual care).
Outcomes
The primary outcome for the IPD meta-analysis will be
time to all-cause mortality. Secondary outcomes are:
death related to HF, cardiovascular death, all-cause hos-
pital admission, hospital admission for HF, adverse events,
and quality of life.
For studies that do not provide IPD, we will collect ag-
gregate data relating to four levels of specification of out-
come measures as proposed by Zarin et al. [17]: domain
(for example quality of life), specific metric (for example
Living with Heart Failure Minnesota Questionnaire),
specific metric used to characterize each participant’s
results (for example change from baseline), and method
of aggregation (for example mean change and 95% CI).
We have grouped the outcomes into the following do-
mains: all-cause mortality, cause-specific mortality (for
death related to HF and death from any cardiovascular
cause); harms (all-cause hospital admission, hospital ad-
mission for HF, other serious adverse events); and quality
of life (see Quality Assessment section for justification for
these domains).
Language
No language restrictions will apply.
Search methods for identification of studies
We initially used published systematic reviews [6-9] to
identify relevant trials. We will search the following elec-
tronic databases: MEDLINE, EMBASE, The Cochrane
Library and ISI Web of Science (Citations Index andConference Proceedings) using the search strategy shown
in Additional file 1. We will search the World Health
Organization International Clinical Trials Registry Plat-
form (WHO ICTRP; http://apps.who.int/trialsearch/) and
Current Controlled Trials (http://www.controlled-trials.
com) to identify trials in progress. We will also review the
reference lists of all full-text papers and correspond with




Two members of the review team will independently tri-
age the titles and abstracts identified by the search to re-
move those that are clearly inappropriate. The remaining
papers will have clear inclusion criteria applied to them.
Disagreements about study inclusion will be resolved by
discussion with a third review author. All trials excluded
from the review will be given reasons for exclusion, such
as 'not a randomized trial' or 'inappropriate control'. All
RCTs in languages other than English will be translated
into English. The English texts of RCTs reported in other
languages will be made available to all collaborators.
Establishing a collaboration
Authors of eligible studies will be invited to join the col-
laboration by providing us with IPD. We will identify
contact information from the published RCT or an online
search. We will contact the main trial author (correspond-
ing author) and provide them with the IPD meta-analysis
protocol and a cover letter explaining what the study is
about. If we receive no response from the corresponding
author, another investigator from the study will be
contacted.
Quality assessment
We will assess studies as having a low, unclear, or high
risk of bias within the following domains: random se-
quence generation (selection bias); allocation conceal-
ment (selection bias); blinding of participants, personnel,
and outcome assessors (performance and detection bias);
incomplete outcome data (attrition bias); selective out-
come reporting (reporting bias); and other sources of
bias. This assessment is based on current Cochrane Col-
laboration guidelines [18], but if any updated guidelines
are published by the time of reporting, we will use those.
For blinding and incomplete outcome data, we will as-
sess risk of bias separately for the pre-specified outcome
domains (all-cause mortality, cause-specific mortality,
adverse events, and quality of life). We have separated
all-cause mortality from cause-specific mortality because
cause-specific mortality may be at risk of bias, depend-
ing on whether or not the person assigning the cause of
death was blinded to the allocated intervention.
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mation to inform the risk of bias assessments. Trial authors
(collaborators) will be asked to provide a study protocol, if
available. If not, they will be asked to clarify uncertainties
arising from reporting of their study with respect to in-
formation needed for the risk of bias assessment.
Two members of the review team will independently
assess the risk of bias in each included study from all
available information using the domain-based evaluation
tool described in the Cochrane Handbook for Systematic
Reviews of Interventions [18]. Disagreements will be re-
solved by discussion with a third review author. The as-
sessment for incomplete outcome data and selective
outcome reporting will be used only for studies for which
IPD is not provided. Blinding of participants, healthcare
providers, and outcome assessors will be judged as low
risk for mortality, which is an objective outcome.
We will search the grey literature extensively to check
for publication bias. We will contact all authors of relevant
unpublished studies and request data from their trials.
Publication bias in studies included in the meta-analysis
will be evaluated with a funnel plot (a plot of the effect
sizes against their standard errors) and trend tests.
Development of the database
Data collection
IPD will be sought from all included RCTs and collated
into a single database. We will request the data for all
randomized patients. We will provide authors with a list
of data items we require (Table 1), but we will accept
trial data in all formats in order to minimize the amount
of work for trial authors and to ensure maximum par-
ticipation. We will also request the formal data diction-
ary for the dataset (table of information about the data
elements), the data collection schedule (time points at
which data were collected) and 'process' data describing
actions conditional on BNP measurements.
Raw data can be transferred by a variety of secure
methods (courier, secure email, or secure electronic
transfer) depending on the preference of the authors’ in-
stitutions. All raw data will be stored on a secure server.
Raw datasets will be saved in their original formats and
then converted to a common format by renaming and
labeling the variables for each study in a consistent
manner. We will develop a framework for mapping and
classifying sufficiently similar variables; this will be dis-
cussed and agreed within the Collaborative Group, and
carefully documented.
Data checking
We will carry out various checks on the data (see exam-
ples below), and discuss and clarify discrepancies with
study authors. For each variable, we will calculate the
proportion of missing observations and compare thiswith data in the original publication. We will carry out
range checks for all included variables to ensure that all
values are reasonable, and tabulate categorical variables
and check against the values tabulated in the original
publication. Datasets will be combined to form a new




We will use standard meta-analysis methods incorporat-
ing all available IPD. All analyses (other than for adverse
effects) will be performed on an intention-to-treat basis.
The primary outcome will be time to all-cause mortality,
defined as the time from randomization to death from
any cause, which will be analyzed by survival methods.
HRs will be estimated using Cox regression models
within each trial. The estimated log HRs will be com-
bined across studies using standard fixed-effect meta-
analysis and random-effects meta-analysis, along with
prediction intervals to represent heterogeneity. Appro-
priate regression models will be used to estimate ORs
for adverse effects (taking a per-protocol approach).
Standardized mean differences will be computed for
quality of life if different scales are used in different
trials.
Subgroup effects will be estimated by estimating treat-
ment × covariate interaction terms within studies, and
combining these across studies in the same way [12].
Covariates defining subgroups will be: age, gender, type
of HF, severity of HF, baseline BNP levels, NYHA class,
LVEF, BP, BMI, AF, diabetes, cardiomyopathy, and risk
score for mortality. Further analyses will investigate
study-level variables such as BNP-guided intervention
characteristics (comparisons to be specified when study-
level data have been extracted) using meta-regression.
Forest plots will be produced for overall effects and for
interaction effects. Interaction effects will be interpreted
by applying them to meta-analyses of the participants in
a reference subgroup (for example, when looking at the
effect in males versus females, the meta-analytic inter-
action coefficient will be added to a meta-analytic esti-
mate of the HR for females only to obtain an estimate of
the HR for males). As above, we intend to present
random-effects estimates, along with prediction intervals
to represent heterogeneity.
Inclusion of aggregate data
For trials that do not provide IPD, we will undertake
additional analyses in which we combine IPD when they
are available with aggregate data when they are not. We
will seek estimates of HRs from reports of studies not
providing IPD [19] and combine these with estimated
HRs derived from the IPD. If HRs are unavailable for a
Table 1 List of data items required
Type of data
Study level Country in which study was carried out
Number of participants randomized
Number allocated to the BNP group
Number allocated to the standard care group
Setting (primary care, hospitals, specialist clinics)
Date first patient randomized
Date final patient randomized
Date of final follow-up
Did the study measure quality of life (state
tool that was used)
Did the study measure heart failure risk score
(state tool that was used)
Details of intervention (frequency of testing,
actions, etc.)
Details of comparator (frequency of review,
actions, etc.)
Individual participant Variables collected at study entry
Demography Age
Sex
Body mass index (or weight and height)
Smoking status
Date of entry into study/date of randomization
Allocated to BNP or standard care
Centre if multi centre





Previous peripheral artery disease
Diabetes status (including type)
History of hypertension
History of atrial fibrillation
History of chronic obstructive pulmonary disease
Pacemaker in situ
Implantable cardioverter defibrillator in situ
Heart failure risk score (if measured)
Individual participant Variables collected at each visit (data required
for all visits including baseline visit)
Date of visit
Clinical NYHA class




























Quality of life If collected (derived scores if available)
Individual participant Clinical outcomes (data required for all




Date of hospital admission/cardiovascular event
Date of hospital discharge
Details of reason for admission/cardiovascular
event (for example heart failure, non fatal
myocardial infarction, non-fatal stroke, new atrial
fibrillation, fitting of pacemaker/CRT device/im-
plantable cardioverter defibrillator)
Lost to follow-up? Date of last follow-up
ACE, angiotensin-converting enzyme; CABG, coronary artery bypass grafting
CRT, cardiac resynchronization therapy; BNP, B-type natriuretic peptide;
NT-BNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart
Association; PCI, percutaneous coronary intervention.
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a combined analysis of the IPD and aggregate data, using
all-cause mortality (rather than time to all-cause mortality)
and a Bayesian hierarchical model [20]. Such a model
also allows limited investigation of patient-level effect
modifiers, by separating within-study and between-study
relationships [14].
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We plan to conduct a sensitivity analysis by restricting the
analysis to trials classified as having low risk of bias over-
all. We will also conduct a sensitivity analysis restricting
the analysis to trials with good allocation concealment, as
this has been shown to be an important source of bias in
RCTs [21,22]. We may additionally implement one-stage
models for IPD as sensitivity analyses [23,24].
Checking for publication and data availability bias
We will follow the recommendations set out by Ahmed
et al. [25] to examine the likelihood of publication bias
and data availability bias. We will examine funnel plots
to investigate association between study size and effect
size (which could be due to publication bias), with and
without studies lacking IPD. We will describe study-level
and patient-level characteristics of included studies. We
will report the meta-analysis of IPD from trials that have
supplied IPD, and a meta-analysis that combines the indi-
vidual participant data with the aggregate data from the
trials lacking individual participant data (if we do not
obtain IPD from all the eligible trials).
Further development of Statistical Analysis Plan
The analyses described above are the main analyses we
propose to conduct. Modifications and/or additional
analyses may be indicated as the project progresses. We
will write a more detailed statistical analysis between re-
ceipt of the data and the full data analysis, in which we
will specify how covariates will be modeled (for example
whether quantitative patient-level characteristics such as
age are treated as continuous or categorical).
How the IPD collaboration will work
We have set up a Management Group, including mem-
bers from the Bristol Clinical Trials and Evaluation Unit
(see http://cteu.bris.ac.uk/), a UKCRN-registered trials
unit at the University of Bristol, and a Professor of Evi-
dence Synthesis at the University of Bristol. The Man-
agement Group will be responsible for contacting and
liaising with study authors, data collection, checking and
analyses, interpretation of findings, and preparing manu-
scripts for publication.
The IPD meta-analysis Collaborative Group will in-
clude all members of the Management Group, clinicians
with expertise in HF, a health economist, and a represen-
tative from each of the included trials. New collaborators
will be invited as eligible trials are completed. The Man-
agement Group will liaise between members of the Col-
laborative Group and organize all necessary interactions
between study members. Members of the Collaborative
Group will be consulted at key stages of the project, and
given the opportunity to participate in decision-makingregarding the statistical analyses to be included in the Stat-
istical Analysis Plan and interpretation of the findings.
Publication policy
All publications resulting from the IPD meta-analysis
will be in the name of the Collaborative Group, with the
contribution of members being described at the end of
the paper. Manuscripts will be prepared by the Manage-
ment Group and circulated to all members of the Col-
laborative Group for comment prior to submission for
peer review. All collaborators will be expected to consult
with, and collate comments from, colleagues from the
trials they represent.
Confidentiality, data storage, and handling
The anonymized dataset supplied by each collaborator
and the final IPD dataset will be used only for the pur-
poses stated in this protocol and analyses set out in the
analysis plan. Any additional analyses will require the
approval of every member of the Collaborative Group.
All datasets will be stored in password-protected files on
a secure computer accessible only by members of the
Management Group, and archived in accordance with
patient data archiving procedures required by the UK
National Health Service (NHS). The datasets will not be
shared with anyone outside the Collaborative Group
without the express permission of each collaborator.
Ethical issues
The IPD meta-analysis is exempt from ethics approval
because we will be collecting and synthesizing data from
previous clinical trials in which informed consent has
already been obtained by the trial investigators, and our
meta-analysis will be addressing very similar questions
to the research question for which the data were col-
lected (and to which patients gave consent). Moreover,
we will request contributors only to submit pseudoano-
nymized datasets (that is, the key linking study number
to identifiable patient data will be retained by the con-
tributor and not shared with the project team). Each
main trial author will be allowed to specify any additional
restrictions on data usage or storage (beyond those stated
above) that they may wish to impose.
Dissemination plans
Findings from both meta-analyses will be reported in
line with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [21]. We will also
adhere to additional reporting guidelines recommended
for IPD meta-analysis [16].
Discussion
This IPD meta-analysis will update an existing IPD meta
analysis of 8 RCTs [13]. It will allow us to estimate the
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patient characteristics modify treatment benefit, and iden-
tify relevant subgroups of patients who are likely to benefit
most from BNP-guided therapy.
Registration
The protocol for the IPD meta-analysis has been registered
with PROSPERO, the international prospective register of
systematic reviews, (PROSPERO 2013: CRD42013005335).
Additional file
Additional file 1: Search strategy: MEDLINE (Ovid) 1950 to present.
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